

New Jersey Bioscience Center Newsletter

THIRD QUARTER 2023

Life Sciences Ecosystem News in New Jersey

[Tevogen Bio Listed on NYSE](#) (Warren)
Tevogen Bio is expected to become a publicly-traded company on the New York Stock Exchange in the fourth quarter of 2023, with a value of approximately \$1.2 billion.

[UroGen Pharma Announces \\$120 Million Private Placement](#) (Princeton)

[Cormedix Inc. Announces Pricing of \\$40 Million Public Offerings](#) (Berkeley Heights)

[Tonix Pharmaceuticals Announces Closing of \\$7 Million Public Offering](#) (Chatham)

[RVL Pharmaceuticals plc Announces \\$5 Million Registered Direct Offering](#) (Bridgewater)

[Celularity Inc. Announces \\$3 Million Registered Direct Offering](#) (Florham Park)

[Sonnet BioTherapeutics Announces \\$2.25 Million Registered Direct Offering and Concurrent Private Placement](#) (Princeton)

[Astellas Pharma Closes \\$5.9B acquisition of Iveric Bio - NJBIZ](#)

Astellas completed its previously announced \$5.9 Billion acquisition of Iveric Bio Inc., an early-stage biopharmaceutical company based in Parsippany.

New Jersey Bioscience Center In The News

Welcome Zena Therapeutics !!!

[Zena Therapeutics](#) is a startup biotech company focused on developing new drugs to treat alcohol and substance abuse as well as anxiety disorders. The company aims to mitigate the harmful impacts of poly-substance use and prevent future overdose fatalities. The Rutgers University spin-out company just recently moved into the Incubator at North Brunswick.

[Lactiga Receives FDA 'Rare Pediatric Disease' Designation](#)

New Jersey Bioscience Center - Incubator at North Brunswick (Incubator at North Brunswick) resident, Lactiga, is a biotechnology company developing novel biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases (PID). The company is hoping to unlock the full therapeutic value of human breastmilk to create the next generation of anti-infectives. Recently, [the company received the U.S. Food and Drug Administration's \(FDA's\) 'Rare Pediatric Disease' Designation for its biologic, LCTG-001, a mucosal antibody replacement therapy.](#)

Founder's Profile - Dr. Neil Goldstein, Co-Founder & CSO of [Skunkworx Bio](#)

Incubator at North Brunswick resident, SkunkWorx Bio, integrates biologic wet lab design with computational biology. The company is developing a new era of precision medicines to create new cancer immunotherapies. Dr. Goldstein has co-authored 70+ publications in peer-reviewed journals and books, numerous abstracts, and was a co-inventor on 15 issued patents; he has contributed to the development of three drugs that are currently on the market or in human clinical trials and has developed several preclinical drug leads for oncology, autoimmunity, and immunological deficiencies. He has also helped launch numerous start-up biotech companies. Dr. Goldstein received his PhD in Microbiology from the Waksman Institute of Microbiology at Rutgers University and did his postdoctoral work at the Wistar Institute.

[OneOncology Selects Smirta's OncoSmart® Platform](#)

OneOncology, the second largest group of Community Oncology centers, has chosen Smirta's OncoSmart(R) platform as the preferred solution for its group of 300 Infusion Centers. Smirta is a resident of the Incubator at North Brunswick.

Quintara Launches Sequencing Services

[Quintara LLC](#), a resident of the Incubator at North Brunswick, is a biotechnology and bioinformation service company. The company can provide DNA sequencing, DNA synthesis, cloning, gene editing and DNA genomic data analysis. [Han Zhang](#) is Co-Founder and Chief Executive Officer.

Incubator Labs at the New Jersey Bioscience Center Research Park

The [Incubator at North Brunswick](#) will have labs available in early 2024. [Email](#) or call Lenzie Harcum (732-839-1880) with any questions or to request a tour.

New Jersey Bioscience Center Alumni In The News

[Ascendia Pharmaceuticals Receives IND Approval](#)

[Ascendia Pharma](#), a graduate of the Incubator at North Brunswick and a current resident of New Jersey Bioscience Center, recently announced that its novel formulation for clopidogrel received Investigational New Drug (IND) approval. The [specialty CDMO, developed the formulation in partnership with AcuteBio, LLC.](#)

[Amicus Announces Approval/Launch of New Pompe Disease Therapy in UK & EU](#)

Incubator at North Brunswick graduate [Amicus Therapeutics](#) recently announced that the Medicines and Healthcare products Regulatory Agency of the United Kingdom had granted marketing authorizations for Pombiliti + Opfolda for adults living with late-onset Pompe disease. Pombiliti + Opfolda is a unique two-component therapy.

[Visikol Founder Appointed President of NJII](#)

In August, Michael Johnson, was named the new President of the [New Jersey Innovation Institute](#) at New Jersey Institute of Technology. Visikol is a graduate of the Incubator at North Brunswick. Under the leadership of co-founders Johnson and Tom Villani, Visikol's rapid growth has continued since its founding in 2016 at Rutgers University.

[PharmaNest Launches New Product](#)

Incubator at North Brunswick graduate PharmaNest recently launched its Digital Pathology Spatially Resolved, Quantitative Tissue Panels to Quantify Tissue Injury and Inflammation in the Context of Fibrotic Conditions.

[PDS Biotech Announces Submission of Phase 3 Protocol to FDA](#)

Incubator at North Brunswick graduate PDS Biotech recently announced its submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial. VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA in recurrent or



NEW JERSEY
BIOSCIENCE CENTER
INCUBATOR AND STEP-OUT LABS
AT NORTH BRUNSWICK

NEW JERSEY BIOSCIENCE CENTER
675 US-1, North Brunswick
Township, NJ 08902

New Jersey Bioscience Center Newsletter

THIRD QUARTER 2023

Life Sciences Ecosystem News in New Jersey

JLL: Pharmaceutical/life sciences remains New Jersey's most active business sector | ROI-NJ

Study: New Jersey ranks No. 2 for best places to live in the US in 2023 (news12.com)

Enzene Biosciences announces a new 55,000-square-foot facility and plans to bring 300 jobs to Princeton area. Operations in the new facility, the company's first location outside of India, are expected to begin in June 2024.

Kyowa Kirin Opens New Jersey Headquarters - Japan-based Kyowa Kirin has opened a new facility in Princeton that will serve as its North American headquarters. At almost 80,000 square feet.

Funding, Grants and Incentives for Life Science Companies

[NJEDA Board Approvals Expand List of New Jersey Innovation Evergreen Fund Qualified Venture Firms](#)

The New Jersey Economic Development Authority (NJEDA) this month approved three additional venture capital firms as Qualified Venture Firms (QVFs) in the New Jersey Innovation Evergreen Fund (NJIEF). With these latest approvals, a total of 10 QVFs can each access up to \$12.5 million annually per investor from the NJIEF to co-invest in innovative, high-growth New Jersey-based businesses. The NJIEF is a first-of-its-kind tool to increase New Jersey startups' access to venture capital and strategic resources.

[Governor Announces Additional \\$20M in Funding for NJ Manufacturing Voucher Program](#)

In July, Governor Phil Murphy highlighted the additional \$20 million included in the Fiscal Year 2024 budget to boost the NJEDA's [New Jersey Manufacturing Voucher Program](#) (MVP) – bringing the program's total funding to \$53 million. MVP, developed in 2022 as a pilot program, provides manufacturers vouchers to purchase equipment they need to improve their operations and upgrade their businesses.

Upcoming Events for NJ's Life Science Community

Sept 19 [BioNJ Entrepreneurs Exchange](#) - virtual meet and greet

Sept 19 [AI in Drug Discovery](#) at VentureLink in Newark

Sept 21 [BioNJ Health Equity in Clinical Trials Best Practices Webinar](#)

Sept 28 [Science Matters: New Jersey Newcomers Blazing New Trails](#) – an event from New Jersey Bioscience Center, in partnership, with Princeton BioLabs

October 4 [Stevens - Technology Is Transforming the Biopharmaceutical Industry](#)

October 6 [2023 BioNJ C-Suite Summit](#)

October 25 Annual [Rutgers iJOBS](#) Symposium

October 26 [BioLabs Investor Day 2023 Princeton](#) - startups must apply by Sept 22nd deadline

November 1 [2023 AI & Digital Health Day - BioNJ](#) – New event from BioNJ

November 16 [2023 BioNJ Patient Advocacy Summit](#)